The present disclosure relates to compounds that act as protein kinase inhibitors, especially CK1δ and/or CK1ε inhibitors, which can be used to treat a serine threonine kinase-dependent disease and condition, such as neurodegenerative diseases like Alzheimer's Disease, and the synthesis of the same. Further, the present disclosure teaches the utilization of such compounds in a treatment for neurodegenerative diseases, including Alzheimer's disease.

The present invention relates to the field of organic chemistry and pharmacology and describes novel asymmetric derivatives of polyphenols of the dinaphthalene series of general Formula (I) or general Formula (II), a process of preparing thereof and use thereof as antiviral agents.

##STR00001##

The present invention relates to the field of organic chemistry and pharmacology and describes novel asymmetric derivatives of polyphenols of the dinaphthalene series of general Formula (I) or general Formula (II), a process of preparing thereof and use thereof as antiviral agents.

##STR00001##

Disclosed in the present invention are a perinaphthenone compound and the use thereof. The compound can bind to E3 ubiquitin ligase tripartite motif 25 (TRIM25), thereby facilitating the recognition of TRIM25 to a pathogen and inducing proteasome-dependent ubiquitination degradation of the pathogen protein. The compound is expected to be used as a ligand for TRIM25 and have a broad application, for example, for preparing a PROTAC molecule. Therefore, the compound has good research and development value and application prospects.

Disclosed in the present invention are a perinaphthenone compound and the use thereof. The compound can bind to E3 ubiquitin ligase tripartite motif 25 (TRIM25), thereby facilitating the recognition of TRIM25 to a pathogen and inducing proteasome-dependent ubiquitination degradation of the pathogen protein. The compound is expected to be used as a ligand for TRIM25 and have a broad application, for example, for preparing a PROTAC molecule. Therefore, the compound has good research and development value and application prospects.

Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

The present disclosure provides compounds of formula 1 to inhibit or prevent mitochondrial dysfunction by augmenting mitochondrial function. Mitochondrial dysfunction is the hallmark of a wide range of diseases and disorders. Mitochondria are a promising therapeutic target for the detection, prevention and treatment of various human diseases such as cancer, neurodegenerative diseases, ischemia-reperfusion injury, diabetes and obesity.

The present disclosure provides compounds of formula 1 to inhibit or prevent mitochondrial dysfunction by augmenting mitochondrial function. Mitochondrial dysfunction is the hallmark of a wide range of diseases and disorders. Mitochondria are a promising therapeutic target for the detection, prevention and treatment of various human diseases such as cancer, neurodegenerative diseases, ischemia-reperfusion injury, diabetes and obesity.